icon3

Deep Vein Thrombosis (DVT), Potential Market Opportunity & Clinical Pipeline Insights, 2019

  • OI-100
  • |
  • Published date: Apr, 2019
  • |
  • Life Sciences & Healthcare
  • |
  • 0 Pages

Thrombosis is referred to a serious heart condition in which arteries or veins are blocked because of a blood clot in the blood vessel. Based on the location of the clot, it is classified as Venous and Arterial Thromboembolism. Deep vein thrombosis (DVT) is nothing but the forming blood clot in a vein deep in the body. Mostly the deep vein clots occur in the legs, which can cause pain and redness in the legs and swell in the lower leg, foot, and ankle. It is one of the parts of venous thromboembolism (VTE), in which the blood clots that are formed in the deep veins of the leg move to the lungs and blocks blood vessels. This leads to the presence of low oxygen levels in the blood that will cause damage to the lungs known as pulmonary embolism. The approach for diagnosing DVT has evolved over the years. Actually, anticoagulation therapy is used to treat DVT, whereas procedures including thrombolysis and placement of inferior vena cava filters are kept for a special situation.


Market Overview


An estimated 10 million population is affected by Thrombosis worldwide every year. Treatment includes thrombolytic and anticoagulants. The study of DVT treatment market includes Heparin, Apixaban, Dabigatran, Rivaroxaban, Edoxaban, Warfarin, Compression Therapy, Inferior Vena Cava Filter, and Thrombolytic Therapy. Anticoagulant therapy remains the important stay of medical therapy for deep venous thrombosis (DVT) because it is noninvasive; it treats most patients (approximately 90%) with no immediate demonstrable physical sequelae of DVT. While parenteral anticoagulants and oral vitamin K antagonists (e.g., warfarin) have been used for many decades, the recent development of novel oral anticoagulants has provided clinicians with an expanding set of therapeutic options for DVT.


The FDA approved drugs include apixaban (Eliquis), dabigatran (Pradaxa), rivaroxaban (Xarelto), Savaysa (edoxaban), and betrixaban (Portola), which are alternatives to warfarin to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). Apixaban, edoxaban, rivaroxaban, and betrixaban inhibit factor Xa, whereas dabigatran is a direct thrombin inhibitor. The clinical pipeline consists of more number of studies with most of the studies found under phase 3 stage of clinical trials compared to early phase, phase1, and phase 2 clinical trials. The drugs in phase 3 stage of clinical trial development include Tinzaparin by LEO Pharma/Novo Nordisk, Enoxaparin by Sanofi, Dalteparin by Pfizer, Heparin, Warfarin, acetylsalicylic acid, and others.


Globally, development of efficient and advanced technology, the rising awareness among people regarding present treatments for deep vein thrombosis, increase in government initiatives across the globe, growth in prevalence and incidence rate of deep vein thrombosis are the prime growth drivers of the DVT treatment market. Additionally, an increase in adoption of DVT treatment in emerging economies including China, India, and others, will create new opportunities for the DVT treatment market. However, the higher cost of the research and development, and complex government regulatory approvals are the key restraints for the DVT treatment market.


Key Developments



  • In June 2018, Biogen entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007, a plasminogen inhibitor, and backup compounds.

  • In Jan 2019, the first-in-human case using the new deep vein thrombosis (DVT) device Vetex thrombectomy catheter (Vetex Medical) has recently been completed human trial in a multicentre study. The device has the potential in reducing hospital stays and costs associated with DVT treatment.


Segmentation


It segments the pipeline molecules based on different phases of drug development including, therapies employed, route of administration (RoA), mechanism of action (MoA), therapeutic modality (Heparin, Apixaban, Rivaroxaban, Edoxaban, Dabigatran, Warfarin,Inferior Vena Cava Filter, Thrombolytic Therapy, and  Compression Therapy), and the targets for the drugs under development. In the current drug pipeline, the most preferred RoA remains through the oral mode, with close to 43% of the pipeline molecules administered through this mode.


Major players involved in the deep vein thrombosis market development include Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Inc., Daiichi Sankyo Co. Ltd., Johnson & Johnson, Abbott Laboratories, Merck & Co., and Astellas Pharma Inc.

Report Description: The report covers in-depth analysis on Deep Vein Thrombosis (DVT) Pipeline Insights, 2019. The report assesses the Deep Vein Thrombosis (DVT) pipeline by stage of development (early development, pre-clinical, clinical and in approval), by application (Embolism, Pulmonary embolism, Stroke, Venous thromboembolism, and others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.


The report includes in-depth company profiles of key players in Deep Vein Thrombosis (DVT) Pipeline. The company profile includes key information on overview, financial highlights, product portfolio, business strategies, and key recent developments.


The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.


Scope:



  • Provides detailed analysis of the product pipeline structure along with forecast of the various segments and sub-segments of the Deep Vein Thrombosis (DVT) Pipeline.

  • Provides a comparative analysis of key marketed products and pipeline Deep Vein Thrombosis (DVT)

  • Provides key information on players involved on the Deep Vein Thrombosis (DVT)Pipeline.

  • Provides a complete overview of market segments and the regional outlook of Deep Vein Thrombosis (DVT) Pipeline.

  • Provides in-depth coverage of key news related toDeep Vein Thrombosis (DVT) Pipeline, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates

Our research works on a holistic 360° approach to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involve the following steps:




  • Data Collation (Primary & Secondary)




  • In-house Estimation (Based on proprietary databases and Models)




  • Market Triangulation




  • Forecasting




  • Market-related information is assembled from both primary and secondary sources. 






  • Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services. 





  • Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others. 





  • Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. 




REPORT YOU MIGHT BE INTERESTED

Choose Licence Type

$2,450.00
$3,850.00


(For Corporate Licence Only) Complementary
Credit card Logo
Inquiry Before Buying

Related Reports


Contact Us

Email Us at: sales@optimainsights.org | Reach Us at: +91 966 6620 365 | +1 424 2554 365 (US)